R
Robert W. Chen
Researcher at City of Hope National Medical Center
Publications - 67
Citations - 1802
Robert W. Chen is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Brentuximab vedotin & Transplantation. The author has an hindex of 16, co-authored 67 publications receiving 1462 citations. Previous affiliations of Robert W. Chen include Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Robert W. Chen,Pier Luigi Zinzani,Michelle A. Fanale,Philippe Armand,Nathalie A. Johnson,Pauline Brice,John Radford,Vincent Ribrag,Daniel Molin,Theodoros P. Vassilakopoulos,Akihiro Tomita,Bastian von Tresckow,Margaret A. Shipp,Yinghua Zhang,Alejandro D. Ricart,Arun Balakumaran,Craig H. Moskowitz +16 more
TL;DR: Pembrolizumab was associated with high response rates and an acceptable safety profile in patients with rrHL, offering a new treatment paradigm for this disease.
Journal ArticleDOI
Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
Michelle A. Fanale,Steven M. Horwitz,Andres Forero-Torres,Nancy L. Bartlett,Ranjana H. Advani,Barbara Pro,Robert W. Chen,Andrew Davies,Timothy M Illidge,Dirk Huebner,Dana A. Kennedy,Andrei R. Shustov +11 more
TL;DR: Brentuximab vedotin, administered sequentially with CHOP or in combination with CHP, had a manageable safety profile and exhibited substantial antitumor activity in newly diagnosed patients with CD30(+) PTCL.
Journal ArticleDOI
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Stephen M. Ansell,Michael B. Maris,Alexander M. Lesokhin,Robert W. Chen,Ian W. Flinn,Ahmed Sawas,Mark D. Minden,Diego Villa,Mary Elizabeth Percival,Mary Elizabeth Percival,Anjali S. Advani,James M. Foran,Steven M. Horwitz,Matthew Mei,Jasmine Zain,Kerry J. Savage,Christiane Querfeld,Oleg E. Akilov,Lisa Johnson,Tina Catalano,Penka S. Petrova,Robert A. Uger,Eric L. Sievers,Anca Milea,Kathleen Roberge,Yaping Shou,Owen A. O'Connor +26 more
TL;DR: In this paper, TTI-621 (SIRPα-IgG1 Fc) is a checkpoint inhibitor that activates antitumor activity by blocking the CD47 "don9t eat me" signal.
Journal ArticleDOI
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Michelle A. Fanale,Steven M. Horwitz,Andres Forero-Torres,Nancy L. Bartlett,Ranjana H. Advani,Barbara Pro,Robert W. Chen,Andrew Davies,Timothy M Illidge,Mayur Uttarwar,Shih Yuan Lee,Hong Ren,Dana A. Kennedy,Andrei R. Shustov +13 more
TL;DR: Durable remissions in 50% of patients treated with frontline brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone are demonstrated, suggesting a potentially curative treatment option for some patients with CD30+ peripheral T-cell lymphoma.
Journal ArticleDOI
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
Atish Mohanty,Natalie Sandoval,Manasi Das,Raju Pillai,Lu Chen,Robert W. Chen,Hesham M. Amin,Michael Wang,Guido Marcucci,Dennis D. Weisenburger,Steven T. Rosen,Lan V. Pham,Vu N. Ngo +12 more
TL;DR: It is shown that, compared to wild type (WT), single E36K, Y44D or C47S CCND1 mutations increasedCCND1 protein levels in MCL cell lines, and this findings uncover a new mechanism that is critical for the regulation of CCND 1 protein levels, and is directly relevant to primary ibrutinib resistance in M CL.